Zobrazeno 1 - 10
of 258
pro vyhledávání: '"Hiroyuki Tadokoro"'
The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure
Autor:
Masanori Hirose, Hiroyuki Takano, Hiroshi Hasegawa, Hiroyuki Tadokoro, Naoko Hashimoto, Genzo Takemura, Yoshio Kobayashi
Publikováno v:
Journal of Pharmacological Sciences, Vol 135, Iss 4, Pp 164-173 (2017)
Dipeptidyl peptidase-4 (DPP-4) inhibitors are hypoglycemic agents. DPP-4 inhibitor has cardioprotective effects after transverse aortic constriction (TAC), but role of DPP-4 on cardiac fibrosis after TAC is not well known. Our aim was to determine th
Externí odkaz:
https://doaj.org/article/794d168908f8457895d73c33ca630844
Autor:
Naoko Hashimoto, Kento Ikuma, Yui Konno, Masanori Hirose, Hiroyuki Tadokoro, Hiroshi Hasegawa, Yoshio Kobayashi, Hiroyuki Takano
Publikováno v:
Journal of Pharmacological Sciences, Vol 135, Iss 1, Pp 29-36 (2017)
Dipeptidyl peptidase-4 (DPP-4) inhibitors are relatively new class of anti-diabetic drugs. Some protective effects of DPP-4 on cardiovascular disease have been described independently from glucose-lowering effect. However, the detailed mechanisms by
Externí odkaz:
https://doaj.org/article/7f18c54b3580439e9bfbc6a2000c1363
Autor:
Akari Nagamine, Hiroshi Hasegawa, Naoko Hashimoto, Tomoko Yamada-Inagawa, Masanori Hirose, Yuka Kobara, Hiroyuki Tadokoro, Yoshio Kobayashi, Hiroyuki Takano
Publikováno v:
Journal of Pharmacological Sciences, Vol 133, Iss 1, Pp 42-48 (2017)
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral hypoglycemic agents for patients with type 2 diabetes mellitus and have potential antiatherosclerotic properties. Meanwhile, it is unclear how DPP-4 inhibitors have protective effects
Externí odkaz:
https://doaj.org/article/a7aace2edf7542c59aa801212660c9e4
Autor:
Kenichi Odaka, Ichio Aoki, Junji Moriya, Kaoru Tateno, Hiroyuki Tadokoro, Jeff Kershaw, Tohru Minamino, Toshiaki Irie, Toshimitsu Fukumura, Issei Komuro, Tsuneo Saga
Publikováno v:
PLoS ONE, Vol 6, Iss 10, p e25487 (2011)
BACKGROUND: Transplantation of mononuclear cells (MNCs) has previously been tested as a method to induce therapeutic angiogenesis to treat limb ischemia in clinical trials. Non-invasive high resolution imaging is required to track the cells and evalu
Externí odkaz:
https://doaj.org/article/f6a9827e12f44e1d9fd03aa11f2b5033
The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure
Autor:
Hiroyuki Tadokoro, Hiroshi Hasegawa, Naoko Hashimoto, Yoshio Kobayashi, Genzo Takemura, Hiroyuki Takano, Masanori Hirose
Publikováno v:
Journal of Pharmacological Sciences, Vol 135, Iss 4, Pp 164-173 (2017)
Dipeptidyl peptidase-4 (DPP-4) inhibitors are hypoglycemic agents. DPP-4 inhibitor has cardioprotective effects after transverse aortic constriction (TAC), but role of DPP-4 on cardiac fibrosis after TAC is not well known. Our aim was to determine th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb2d84d4559a46490f6a91494ed79bac
https://doi.org/10.1016/j.jphs.2017.11.006
https://doi.org/10.1016/j.jphs.2017.11.006
Autor:
Yoshio Kobayashi, Masanori Hirose, Hiroyuki Takano, Naoko Hashimoto, Kento Ikuma, Hiroyuki Tadokoro, Yui Konno, Hiroshi Hasegawa
Publikováno v:
Journal of Pharmacological Sciences, Vol 135, Iss 1, Pp 29-36 (2017)
Dipeptidyl peptidase-4 (DPP-4) inhibitors are relatively new class of anti-diabetic drugs. Some protective effects of DPP-4 on cardiovascular disease have been described independently from glucose-lowering effect. However, the detailed mechanisms by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6289013378fceae764212c9841fa2c98
https://doi.org/10.1016/j.jphs.2017.08.005
https://doi.org/10.1016/j.jphs.2017.08.005
Autor:
Masanori Hirose, Yuka Kobara, Hiroyuki Tadokoro, Akari Nagamine, Tomoko Yamada-Inagawa, Naoko Hashimoto, Hiroyuki Takano, Hiroshi Hasegawa, Yoshio Kobayashi
Publikováno v:
Journal of Pharmacological Sciences, Vol 133, Iss 1, Pp 42-48 (2017)
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral hypoglycemic agents for patients with type 2 diabetes mellitus and have potential antiatherosclerotic properties. Meanwhile, it is unclear how DPP-4 inhibitors have protective effects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb1afcf270c8196037ab515363706256
http://www.sciencedirect.com/science/article/pii/S1347861316301724
http://www.sciencedirect.com/science/article/pii/S1347861316301724
Autor:
Yoshio Kobayashi, Akihiko Kubota, Issei Komuro, Hiroyuki Takano, Tomoko Yamada-Inagawa, Hiroyuki Tadokoro, Hiroshi Hasegawa, Haixiu Wang, Yuka Kobara, Masanori Hirose
Publikováno v:
Journal of Molecular and Cellular Cardiology. 91:72-80
Aims Dipeptidyl peptidase-4 (DPP-4) inhibitors are reported to have protective effects on various cells but it is unclear how DPP-4 inhibitors have cardioprotective effects. Our aim was to study the mechanisms of cardioprotective effects by DPP-4 inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c31f1a7a2b055701a0a209c31e63dd3
https://doi.org/10.1016/j.yjmcc.2015.12.026
https://doi.org/10.1016/j.yjmcc.2015.12.026
Autor:
Yoshio Kobayashi, Masanori Hirose, Hiroshi Hasegawa, N. Hashimoto, Hiroyuki Takano, Hiroyuki Tadokoro, G. Takemura
Publikováno v:
European Heart Journal. 38
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c0e0430d1810302e4089de5aab84d81
https://doi.org/10.1093/eurheartj/ehx501.p583
https://doi.org/10.1093/eurheartj/ehx501.p583
Publikováno v:
The Proceedings of the Symposium on Micro-Nano Science and Technology. :20pm3PN214
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5caf09e5c85d73a6f44d824b423c2bfe
https://doi.org/10.1299/jsmemnm.2019.10.20pm3pn214
https://doi.org/10.1299/jsmemnm.2019.10.20pm3pn214